LABS Stock Overview A pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MediPharm Labs Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for MediPharm Labs Historical stock prices Current Share Price CA$0.065 52 Week High CA$0.10 52 Week Low CA$0.06 Beta 0.98 1 Month Change 8.33% 3 Month Change -7.14% 1 Year Change -7.14% 3 Year Change -67.50% 5 Year Change -97.59% Change since IPO -97.05%
Recent News & Updates
Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023) Nov 17
New minor risk - Share price stability Nov 14
MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024 Nov 11
MediPharm Labs Corp. Announces Executive Changes Oct 17
MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares Oct 11
New major risk - Revenue and earnings growth Sep 16 See more updates
Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023) Nov 17
New minor risk - Share price stability Nov 14
MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024 Nov 11
MediPharm Labs Corp. Announces Executive Changes Oct 17
MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares Oct 11
New major risk - Revenue and earnings growth Sep 16
Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations Aug 15
MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024 Aug 09
MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024 May 31
MediPharm Labs (TSE:LABS) Is Using Debt Safely May 29
First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat May 17
MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024 May 10
Consensus estimates of losses per share improve by 25% Apr 03
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 28
MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024 Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost Mar 23
New minor risk - Share price stability Mar 23
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet? Jan 10
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 17
Consensus revenue estimates decrease by 11% Nov 15
MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023 Nov 09
New minor risk - Share price stability Oct 09 Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million. Oct 06
MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp Oct 05
MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market Sep 28
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry? Sep 06
Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients Sep 01
CEO & Director exercised options to buy CA$130k worth of stock. Aug 25
Consensus revenue estimates decrease by 25%, EPS upgraded Aug 21
New major risk - Financial position Aug 16
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 16
MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023 Aug 11
MediPharm Labs Corp. Provides Update on US FDA Status Aug 02
CEO & Director exercised options to buy CA$89k worth of stock. Jun 29
CEO & Director exercised options to buy CA$93k worth of stock. May 26
Consensus EPS estimates upgraded to CA$0.045 loss, revenue downgraded May 22
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 17
MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023 May 11
High number of new and inexperienced directors May 01
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable Apr 17
Consensus revenue estimates increase by 47%, EPS downgraded Apr 02 MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million. Dec 24
Consensus forecasts updated Nov 21
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 16
MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022 Nov 10
Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS). Oct 08
Consensus revenue estimates fall by 20% Aug 22
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook Aug 20
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 16
MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022 Aug 12
Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million. Jul 12
Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp Jul 01
Consensus revenue estimates fall by 27% May 23
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates May 21
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 17
MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022 May 13
Price target decreased to CA$0.25 Apr 27
High number of new and inexperienced directors Apr 27
MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022 Apr 23 MediPharm Labs Corp. Announces Management Changes
Consensus revenue estimates fall by 13% Apr 07
Medipharm Labs Corp Launches CBG and Water-Soluble Products Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade Apr 06
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 02
MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022 Mar 31
MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022 Mar 30
Is MediPharm Labs (TSE:LABS) Using Too Much Debt? Mar 07
Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF Feb 24
CEO of Asia Pacific & Director recently sold CA$87k worth of stock Nov 25
MediPharm Labs Expands CBN Portfolio with Two New Products Nov 24
Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020) Nov 17
Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020) Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet? Aug 18
Consensus forecasts updated Aug 17
Price target decreased to CA$0.65 Aug 17
MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence Jul 15
Founder & Chairman of the Board recently sold CA$483k worth of stock Jun 17
Independent Director recently bought CA$304k worth of stock May 29
MediPharm Labs Launches High-CBD Wellness Oils in Quebec May 27
Consensus revenue estimates fall to CA$36.0m May 24
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates May 23
Price target decreased to CA$0.75 May 19
First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020) May 19
Consensus revenue estimates fall to CA$49.7m Apr 07
Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019) Apr 03
MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement Mar 11
Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products Mar 10
Independent Director recently bought CA$200k worth of stock Mar 10
MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million. Mar 06
New 90-day low: CA$0.48 Mar 06
Interim Chief Financial Officer has left the company Feb 10
New 90-day high: CA$0.90 Feb 10
MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021 Jan 31 Shareholder Returns LABS CA Pharmaceuticals CA Market 7D 0% -2.5% 0.05% 1Y -7.1% -48.3% 17.5%
See full shareholder returns
Return vs Market: LABS underperformed the Canadian Market which returned 17.5% over the past year.
Price Volatility Is LABS's price volatile compared to industry and market? LABS volatility LABS Average Weekly Movement 12.8% Pharmaceuticals Industry Average Movement 12.6% Market Average Movement 8.3% 10% most volatile stocks in CA Market 18.5% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: LABS has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: LABS's weekly volatility (13%) has been stable over the past year.
About the Company MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
Show more MediPharm Labs Corp. Fundamentals Summary How do MediPharm Labs's earnings and revenue compare to its market cap? LABS fundamental statistics Market cap CA$26.72m Earnings (TTM ) -CA$11.75m Revenue (TTM ) CA$39.05m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LABS income statement (TTM ) Revenue CA$39.05m Cost of Revenue CA$25.34m Gross Profit CA$13.71m Other Expenses CA$25.46m Earnings -CA$11.75m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.029 Gross Margin 35.10% Net Profit Margin -30.10% Debt/Equity Ratio 1.3%
How did LABS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 01:55 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MediPharm Labs Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aaron Grey Alliance Global Partners Tamy Chen BMO Capital Markets Equity Research Kimberly Thompson-Hedlin Canaccord Genuity
Show 3 more analysts 
